Repligen (NASDAQ:RGEN) Upgraded to “Buy” at Wall Street Zen

Repligen (NASDAQ:RGEN) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other research firms have also commented on RGEN. UBS Group raised their price target on Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Weiss Ratings cut Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, January 30th. Barclays lifted their price target on shares of Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Finally, Canaccord Genuity Group raised their price target on shares of Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $179.62.

Repligen Price Performance

Shares of RGEN stock opened at $142.18 on Friday. The company has a quick ratio of 7.14, a current ratio of 8.36 and a debt-to-equity ratio of 0.26. Repligen has a 12-month low of $102.96 and a 12-month high of $175.77. The firm has a fifty day moving average of $161.90 and a 200-day moving average of $144.83. The firm has a market capitalization of $8.00 billion, a price-to-earnings ratio of 7,112.56, a price-to-earnings-growth ratio of 2.53 and a beta of 1.13.

Insider Transactions at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the transaction, the director owned 91,821 shares in the company, valued at approximately $14,783,181. The trade was a 0.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO James Bylund sold 2,191 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $151.21, for a total value of $331,301.11. Following the sale, the chief operating officer owned 21,520 shares of the company’s stock, valued at approximately $3,254,039.20. The trade was a 9.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 49,657 shares of company stock worth $7,721,077. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Several large investors have recently modified their holdings of RGEN. Measured Wealth Private Client Group LLC bought a new position in Repligen during the third quarter worth $29,000. Bayforest Capital Ltd bought a new position in shares of Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC acquired a new stake in shares of Repligen in the 4th quarter valued at about $33,000. Hantz Financial Services Inc. increased its position in Repligen by 2,663.6% in the 2nd quarter. Hantz Financial Services Inc. now owns 304 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 293 shares in the last quarter. Finally, CWM LLC raised its stake in Repligen by 67.2% during the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock worth $45,000 after buying an additional 135 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.